| Regulatory
Matters |
| |
Antipsychotics |
| |
Buflomedil |
| |
Dipeptidyl
peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists |
| |
Dronedarone |
| |
Lopinavir/ritonavir |
| |
Methylene
blue injectable |
| |
Modafinil |
| |
Proton
pump inhibitors |
| |
Rosiglitazone |
| |
Rotavirus
vaccination |
| |
Sitaxentan |
| |
Terbutaline |
| |
Topiramate |
|
Safety of Medicines |
| |
Abacavir |
| |
Colchicine |
| |
Daptomycin |
| |
Dronedarone |
| |
H1N1
influenza vaccine (Pandemrix) |
| |
Lenalidomide |
| |
Natalizumab |
| |
Omalizumab |
| |
Seasonal
influenza vaccine |
| Feature |
| |
WHO
Training Course on Pharmacovigilance |